This is a working overview of anti-doping category, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-27 and is reviewed periodically as new material appears.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
AlPhos allows for the mild Pd-catalyzed fluorination of aryl- and heteroaryl triflates. Reported in 2015, this ligand has been used for Buchwald-Hartwig cross-coupling reactions and synthesizing highly regioselective aryl fluorides through Pd-catalyzed fluorination of various activated aryl and heteroaryl triflates and bromides. Its palladium complexes have also been used to prepare aryl thioethers by C–S cross-coupling of thiols with aromatic electrophiles.
Andy Street, the Mayor of the West Midlands, announces that he and his Manchester counterpart, Andy Burnham, are to meet Mark Harper, the Secretary of State for Transport, to discuss proposals for a privately funded alternative to the abandoned Manchester leg of HS2. The UK is to lend several pieces of the Ghana crown jewels back to Ghana 150 years after looting them from the court of the Asante king. 25 January The UK government announces fresh plans to ban the sale of zombie knives, with legislation taking effect from the autumn. Lloyds Banking Group announces plans to cut around 1,600 positions from its branch staff in a reorganisation that it says is because more customers are banking online. 26 January Buckingham Palace confirms that King Charles III has been admitted to hospital for treatment for an enlarged prostate. Jürgen Klopp, currently the longest-serving manager in the Premier League, announces he is departing as manager of Liverpool F.C. after the conclusion of the 2023–24 season, and taking a break from football management. 27 January The UK government suspends funding for the UN agency for Palestinian refugees, UNRWA, after the organisation sacked several officials reported to have been involved in the 7 October attacks on Israel. Kemi Badenoch, the business secretary, asks Henry Staunton to step down as chair of Post Office Limited after 13 months in the role, as the government moves to strengthen governance at the Post Office in the wake of the long-running Horizon IT scandal.
=== Kidney damage === Lithium has been associated with several forms of kidney injury. It is estimated that impaired urinary concentrating ability is present in at least half of individuals on chronic lithium therapy, a condition called lithium-induced nephrogenic diabetes insipidus, or lithium-induced AVP resistance. This occurs because lithium competes with the antidiuretic hormone in the kidney and increases water output into the urine. Clearance of lithium by the kidneys is usually successful with certain diuretic medications, including amiloride and triamterene. Continued use of lithium can lead to more serious kidney damage in an aggravated form of nephrogenic diabetes insipidus. Lithium specifically inhibits function of the aquaporin-2 water channel, leading to impaired reabsorption of water, polyuria, polydipsia, significant hypernatremia, which can lead to CNS symptoms such as confusion, lethargy, and coma. Chronic kidney disease, otherwise known as chronic renal insufficiency (CRI), occurs in 1–5% of people after 10–20 years of lithium treatment. End-stage renal disease occurs in 0.53% of people treated with lithium versus 0.2% in the general population. Kidney harm can be mitigated by keeping the lithium dose as low as possible and dosing lithium once per day at night. Multiple daily doses are associated with more kidney damage. Dosing lithium once per day allows for long periods where the kidney is exposed to low levels of lithium, which minimizes kidney harm.
The Geneva College of Longevity Science (GCLS) is a higher-education institution based in Geneva, Switzerland, focused on postgraduate education, professional training and academic work in longevity science and longevity medicine. Established in 2024, the institution provides programmes concerning ageing biology, preventive medicine, healthy ageing and the translation of geroscience into clinical and professional practice. GCLS offers postgraduate and continuing-education programmes in longevity science and related fields. Its activities also include research and framework development concerning physician education and clinical standards in longevity medicine, as well as academic partnerships and scientific meetings.
Sources: en.wikipedia.org
== Effectiveness == Drug companies nearly universally believe the ODA to be a success. Before Congress enacted the ODA in 1983 only 38 drugs were approved in the USA specifically to treat orphan diseases. In the US, from January 1983 to June 2004, a total of 1,129 different orphan drug designations have been granted by the Office of Orphan Products Development (OOPD) and 249 orphan drugs have received marketing authorization. In contrast, the decade prior to 1983 saw fewer than ten such products come to market. From the passage of the ODA in 1983 until May 2010, the FDA approved 353 orphan drugs and granted orphan designations to 2,116 compounds. As of 2010, 200 of the roughly 7,000 officially designated orphan diseases have become treatable. In 2010, drugmaker Pfizer established a division to focus specifically on the development of orphan drugs as other large pharmaceutical companies focused greater efforts on the orphan drug research. Some critics have questioned whether orphan drug legislation was the real cause of this increase (claiming that many of the new drugs were for disorders that were already being researched anyway, and would have had drugs developed regardless of the legislation), and whether the ODA has really stimulated the production of truly non-profitable drugs; the act also received some criticism for allowing some pharmaceutical companies to make a large profit off of drugs that have a small market but still sell for a high price.
There were no reported injuries. In August 2024, an explosion occurred at Evonik Industries’ chemical facility in Theodore, Alabama, when a railcar containing 70% hydrogen peroxide experienced overpressure. No serious injuries were reported. After the event, Evonik began a phased restart of operations following comprehensive safety inspections.
== Work == The new São Paulo Institute was built in a section of the city named Butantan, at the time a far-away place, near the Pinheiros river, a swampy, sparsely inhabited area. Under Vital Brazil, it soon became an energetic and exemplary research center in vaccines and sera of all kinds, which were produced locally for the prophylaxis and treatment of tetanus, diphtheria, yellow fever, smallpox and several zoonoses (diseases transmitted to humans by animals), such as the dreaded hydrophobia. The Institute came to be well known by his original name, the Butantan Institute, and is still active today. Vital Brazil was convinced since his early work at Butantan that envenomations (poisoning by accidents with venomous animals, such as snakes, scorpions, spiders and batrachia, then the cause of thousands of deaths in Brazil) could be fought with antisera, i.e., antibodies specifically produced for venoms which were proteins or long-chain peptides. A French immunologist, Albert Calmette (1863–1933) had demonstrated this for the first time in 1892, by developing a monovalent serum to treat bites by the Indian cobra (Naja tripudians).
In 2026 the United Nations and the World Food Programme warned that six million people or one third of Somalia's population were facing food crises and that 1.9 million children faced acute malnutrition, primarily due to a severe drought and cut in aid expenditures.
=== Etymology === The English word is from Classical Nahuatl chīlli with the same meaning. The name of the plant is unrelated to that of the country Chile. While pepper originally meant the genus Piper, not Capsicum, the Oxford English Dictionary and Merriam-Webster record both usages. The three primary spellings are chili (common in North America), chile (Central America and parts of the US) and chilli (United Kingdom and former British colonies). The specific dish name "chili con carne" is normally written with one "l" in both American and British English.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.